ELTROMBOPAG THERAPHY IN CASES OF APLASTIC ANEMIA: A CASE REPORT
Abstract
Abstract: Eltrombopag Theraphy In Cases Of Aplastic Anemia: A Case Report. Management of cases of aplastic anemia is challenge. The definitive treatment is bone marrow transplantation, but it is expensive, the complication rate is high and the success rate is still low. Recent evidence shows that eltrombopag theraphy respods to thrombocytopenic conditions, and even other cytopenia. We report an 18 years old man with aplastic anemia with severe pancytopenia. The patient showed an inadequate response to theraphy with eltrombopag theraphy for three months of therapy.
Keywords
Full Text:
PDFReferences
Alvarado LJ, Andreoni A, Huntsman HD, dkk. 2017. Heterodimerization of TPO and IFNγ impairs human hematopoietic stem/progenitor cell signaling and survival in chronic inflammation. Blood;130(suppl 1):4
Alvarado LJ, Huntsman HD, Cheng H, dkk. 2019. Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ. Blood;133:2043-2055
Ding SX, Chen T, Wang T, dkk. 2018. The Risk of Clonal Evolution of Granulocyte Colony-Stimulating Factor for Acquired Aplastic Anemia: A Systematic Review and Meta-Analysis. Acta Haematol;140(3):141-145
Georges GE, Doney K, Storb R. 2018. Severe aplastic anemia: allogeneic bone marrow transplantation as first-line treatment. Blood Adv. Aug 14;2(15):2020-2028
Hwang YY, Chan TSY, Chan FHY, dkk. 2022. Eltrombopag as frontline treatment of aplastic anaemia in routine practice: implications on cost and efficacy. Ann Hematol. Jun;101(6):1163-1172.
Lichtman, AM, Kaushansky K, Prchal JT, dkk. 2017. Aplastic Anemia. William Manual of Hematology Edisi ke sembilan; 33 – 42
Moore CA, Krihnan K. Aplastic Anemia. NCBI. 2022. Tanggal akses: 18 April 2023. Dapat diakses pada: https://www.ncbi.nlm.nih.gov/books/NBK534212-/#_NBK534212_pubdet_
Patel BA, Groarke EM, Lotter J, dkk. 2022. Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study. Blood.Jan 6;139(1):34-43
Peffault de Latour R, Kulasekararaj A, Iacobelli S, dkk. 2022. Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation. Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia. N Engl J Med. Jan 6;386(1):11-23
Sadallah S, Amicarella F, Eken C, dkk. 2014. Ectosomes released by platelets induce differentiation of CD4+T cells into T regulatory cells. Thromb Haemost;112(6):1219-1229.
Sadallah S, Eken C, Martin PJ, Schifferli JA. 2011. Microparticles (ectosomes) shed by stored human platelets downregulate macrophages and modify the development of dendritic cells. J Immunol;186(11):6543-6552.
Scheinberg P. 2018. Activity of eltrombopag in severe aplastic anemia. Blood Adv. Nov 13;2(21):3054-3062.
Shallis RM, Ahmad R, Zeidan AM. 2018. Aplastic anemia: Etiology, molecular pathogenesis, and emerging concepts. Eur J Haematol. Dec;101(6):711-720. doi: 10.1111/ejh.13153. Epub 2018 Oct 10. PMID: 30055055.
Thota S, Patel BJ, Sadaps M, dkk. 2017. Therapeutic outcomes using subcutaneous low dose alemtuzumab for acquired bone marrow failure conditions. British Journal of Haematology.
Vaht K, Göransson M, Carlson K, dkk. 2017. Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000-2011. Haematologica. Oct;102(10):1683-1690
Young NS. 2018. Aplastic Anemia. N Engl J Med. Oct 25;379(17):1643-1656
Zhao X, Feng X, Wu Z, dkk. 2018. Persistent elevation of plasma thrombopoietin levels after treatment in severe aplastic anemia. Exp Hematol ;58:39-43
DOI: https://doi.org/10.33024/jmm.v7i3.10491
Refbacks
- There are currently no refbacks.
Copyright (c) 2023 Jurnal Medika Malahayati
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
